FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892420036> ?p ?o ?g. }

• W2892420036 endingPage "905" @default.
• W2892420036 startingPage "893" @default.
• W2892420036 abstract "Aberrant activation of FMS-like tyrosine kinase 3 (FLT3) is associated with acute myeloid leukemia (AML). Leukemic cells expressing constitutively active FLT3 mutants are resistance to the current cancer therapies (radiotherapy and chemotherapy); hence, there is an increased interest to identify new agents for the treatment of AML. The main aim of this study was evaluating cytotoxic effects of novel pyrimidocyanoacrylates and quinoline derivatives on FLT3 overexpressing cells.Five novel pyrimidocyanoacrylates & 2-chloro 3-carbaldehyde quinolone derivative compounds, E1QAC1, E1QAC2, E1QAC3, E1QAC4, and E1QAC5 were designed and synthesized at the Department of Chemistry, Faculty of Sciences, Ferdowsi University, Mashhad, Iran. FDC-P1 cells expressing human wild-type FLT3 (FD-FLT3-WT) and internal tandem duplication (ITD) mutants (FD-FLT3-ITD) used in this study. The cells maintained in DMEM medium supplemented with 10% fetal calf serum (FCS) and murine granulocyte-macrophage colony stimulating factor (mGM-CSF). Potency for induction of cytotoxicity (IC50 value) and apoptosis was determined after treating the cells with concentration of the compounds by resazurin assay. Bax and Bcl2 activation status was also investigated by Western blot analysis.All the compounds had concentration-dependent effects on inhibition of cell proliferation and induction of apoptosis in both cell lines. E1QAC4 was the most potent compound for inhibition of cell proliferation (with IC50 value of 19 μM) and apoptosis induction in the FLT3-WT cells. However, FD-FLT3-ITD cells were nearly five-times more resistant to all the compounds (except than E1QAC2) that the FLT3-WT expressing cells. Western blotting results also showed that FD-FLT3-ITD cells had lower levels of Bax and higher levels of Bcl2 than the FD-FLT3-WT cells.The five novel heterocyclic compounds (E1QAC1-5) had cytotoxic effects and induced apoptosis in FD-FLT3 cells. Therefore, it is worthwhile to consider them as potential lead compound for development of new therapeutic agents for AML patients." @default.
• W2892420036 created "2018-10-05" @default.
• W2892420036 creator A5003773942 @default.
• W2892420036 creator A5043432487 @default.
• W2892420036 creator A5060962920 @default.
• W2892420036 creator A5077663428 @default.
• W2892420036 creator A5078645015 @default.
• W2892420036 date "2018-12-01" @default.
• W2892420036 modified "2023-09-24" @default.
• W2892420036 title "Induction of cytotoxicity and apoptosis in FLT3 mutant expressing cells using novel pyrimido cyanoacrylates and quinoline derivatives" @default.
• W2892420036 cites W1608710587 @default.
• W2892420036 cites W1971028883 @default.
• W2892420036 cites W1981737096 @default.
• W2892420036 cites W1984358846 @default.
• W2892420036 cites W1990992718 @default.
• W2892420036 cites W2007351520 @default.
• W2892420036 cites W2009816863 @default.
• W2892420036 cites W2010917390 @default.
• W2892420036 cites W2013825789 @default.
• W2892420036 cites W2016883830 @default.
• W2892420036 cites W2022121192 @default.
• W2892420036 cites W2022622009 @default.
• W2892420036 cites W2028415754 @default.
• W2892420036 cites W2050768356 @default.
• W2892420036 cites W2056465113 @default.
• W2892420036 cites W2059861896 @default.
• W2892420036 cites W2060346337 @default.
• W2892420036 cites W2060402045 @default.
• W2892420036 cites W2064194276 @default.
• W2892420036 cites W2065919583 @default.
• W2892420036 cites W2066404978 @default.
• W2892420036 cites W2066755167 @default.
• W2892420036 cites W2069931679 @default.
• W2892420036 cites W2073306644 @default.
• W2892420036 cites W2074730236 @default.
• W2892420036 cites W2076557118 @default.
• W2892420036 cites W2078166953 @default.
• W2892420036 cites W2091023243 @default.
• W2892420036 cites W2092606584 @default.
• W2892420036 cites W2098871697 @default.
• W2892420036 cites W2147759897 @default.
• W2892420036 cites W2155704762 @default.
• W2892420036 cites W2158558881 @default.
• W2892420036 cites W2167504764 @default.
• W2892420036 cites W2170255604 @default.
• W2892420036 cites W2170839629 @default.
• W2892420036 cites W2240399463 @default.
• W2892420036 cites W2274388362 @default.
• W2892420036 cites W2388163742 @default.
• W2892420036 cites W2620653306 @default.
• W2892420036 cites W2736181634 @default.
• W2892420036 cites W2782522317 @default.
• W2892420036 doi "https://doi.org/10.1016/j.biopha.2018.09.001" @default.
• W2892420036 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30372901" @default.
• W2892420036 hasPublicationYear "2018" @default.
• W2892420036 type Work @default.
• W2892420036 sameAs 2892420036 @default.
• W2892420036 citedByCount "3" @default.
• W2892420036 countsByYear W28924200362019 @default.
• W2892420036 countsByYear W28924200362021 @default.
• W2892420036 countsByYear W28924200362023 @default.
• W2892420036 crossrefType "journal-article" @default.
• W2892420036 hasAuthorship W2892420036A5003773942 @default.
• W2892420036 hasAuthorship W2892420036A5043432487 @default.
• W2892420036 hasAuthorship W2892420036A5060962920 @default.
• W2892420036 hasAuthorship W2892420036A5077663428 @default.
• W2892420036 hasAuthorship W2892420036A5078645015 @default.
• W2892420036 hasBestOaLocation W28924200361 @default.
• W2892420036 hasConcept C109316439 @default.
• W2892420036 hasConcept C117262875 @default.
• W2892420036 hasConcept C153911025 @default.
• W2892420036 hasConcept C185592680 @default.
• W2892420036 hasConcept C190283241 @default.
• W2892420036 hasConcept C202751555 @default.
• W2892420036 hasConcept C2778041864 @default.
• W2892420036 hasConcept C2778729363 @default.
• W2892420036 hasConcept C502942594 @default.
• W2892420036 hasConcept C54355233 @default.
• W2892420036 hasConcept C55493867 @default.
• W2892420036 hasConcept C81885089 @default.
• W2892420036 hasConcept C86803240 @default.
• W2892420036 hasConcept C98274493 @default.
• W2892420036 hasConceptScore W2892420036C109316439 @default.
• W2892420036 hasConceptScore W2892420036C117262875 @default.
• W2892420036 hasConceptScore W2892420036C153911025 @default.
• W2892420036 hasConceptScore W2892420036C185592680 @default.
• W2892420036 hasConceptScore W2892420036C190283241 @default.
• W2892420036 hasConceptScore W2892420036C202751555 @default.
• W2892420036 hasConceptScore W2892420036C2778041864 @default.
• W2892420036 hasConceptScore W2892420036C2778729363 @default.
• W2892420036 hasConceptScore W2892420036C502942594 @default.
• W2892420036 hasConceptScore W2892420036C54355233 @default.
• W2892420036 hasConceptScore W2892420036C55493867 @default.
• W2892420036 hasConceptScore W2892420036C81885089 @default.
• W2892420036 hasConceptScore W2892420036C86803240 @default.
• W2892420036 hasConceptScore W2892420036C98274493 @default.
• W2892420036 hasFunder F4320322855 @default.
• W2892420036 hasLocation W28924200361 @default.

• next